Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...

Meta: In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

A Chester man is back home Friday night with quite a story to tell. Steve Joseph captained his 26-foot Boston Whaler over ...